Incontinence outcomeValue
Reduction in leakage episodes (PFMT success)55%
Reduction in leakage episodes (PFMT fail/continued)27.5%
Reduction in leakage episodes (PFMT fail/discontinued)0%
Reduction in leakage episodes (duloxetine continued)55%
Reduction in leakage episodes (duloxetine discontinued)0%
Reduction in leakage episodes (duloxetine discontinued by 12 weeks)42%
Reduction in leakage episodes (duloxetine discontinued by 52 weeks)55%
Days on duloxetine if discontinued by 12 weeks35 days
Weeks on duloxetine for those who discontinued by 52 weeks32 weeks

From: Appendix F, Cost effectiveness analysis for duloxetine

Cover of Urinary Incontinence
Urinary Incontinence: The Management of Urinary Incontinence in Women.
NICE Clinical Guidelines, No. 40.
National Collaborating Centre for Women's and Children's Health (UK).
London: RCOG Press; 2006 Oct.
Copyright © 2006, National Collaborating Centre for Women’s and Children’s Health.

No part of this publication may be reproduced, stored or transmitted in any form or by any means, without the prior written permission of the publisher or, in the case of reprographic reproduction, in accordance with the terms of licences issued by the Copyright Licensing Agency in the UK []. Enquiries concerning reproduction outside the terms stated here should be sent to the publisher at the UK address printed on this page.

The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant laws and regulations and therefore for general use.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.